Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04483349 · ClinicalTrials.gov registry record
Assessment of What Patients and Healthcare Providers Value
A clinical trial of Pancreatic Adenocarcinoma and Gastric Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 397
- Enrollment target
- 1
- Study location
NCT04483349 is a study of Pancreatic Adenocarcinoma and Gastric Adenocarcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 397 participants, below the 99,459-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04483349, a study of Pancreatic Adenocarcinoma and Gastric Adenocarcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 397 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life \[QOL\], cost, experience), and how these patients’ views differ depending on the stage of their therapy (pretreatment, preoperative therapy, post-operative, long-term surveillance, recurrence).
Conditions Studied
Interventions
- OTHER Survey Administration
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2020-06-11 |
| Est. Completion | 2022-08-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04483349
The ClinicalTrials.gov registry entry for NCT04483349 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,459-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Survey Administration is the first listed.
NCT04483349 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04483349 about?
NCT04483349 is a clinical study titled "Assessment of What Patients and Healthcare Providers Value". To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life \[QOL\], cost, experience), and how these patients’ views differ depending on the stage of their therapy (pretreatment, preoperative therapy, post-operative, long-term surveillance, recurren...
What is the current status of trial NCT04483349?
This trial is currently completed. The enrollment target is 397 participants. The study started on 2020-06-11. Estimated completion is 2022-08-11.
What conditions does trial NCT04483349 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT04483349?
The interventions under investigation include: Survey Administration (OTHER).
Who is sponsoring clinical trial NCT04483349?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04483349 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.